RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Oncogenic KRAS mutation is the signature genetic event in the progression and growth of
pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease. Although it …

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …

Technological advancement has opened the door to systematic genetics in mammalian
cells. Genome‐scale loss‐of‐function screens can assay fitness defects induced by partial …

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal
7% 5-year survival rate and is projected to become the second leading cause of cancer …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …

KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The
dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in …

Applying Synthetic Lethality for the Selective Targeting of Cancer | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …